Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.41 |
| ▸ | KIT | P10721 | 4/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932420 | 0.94 | ULK1 (0.46) | ULK1BRD4FGFR3KITRIPK1 | |
| SCHEMBL18918872 | 0.90 | ULK1 (0.45) | ULK1BRD4FGFR3TP53BP1KIT | |
| SCHEMBL18944169 | 0.90 | FGFR3 (0.46) | ULK1BRD4FGFR3TP53BP1KIT | |
| SCHEMBL18932418 | 0.88 | PLK4 (0.51) | ULK1BRD4RIPK1ALDH1A1HPGD | |
| SCHEMBL18918931 | 0.88 | ULK1 (0.46) | ULK1BRD4FGFR3KITRIPK1 | |
| SCHEMBL18944167 | 0.88 | ULK1 (0.46) | ULK1BRD4FGFR3KITRIPK1 | |
| SCHEMBL18932424 | 0.86 | PIN1 (0.46) | ULK1BRD4KITKDM4EALDH1A1 | |
| SCHEMBL18932410 | 0.86 | ULK1 (0.47) | ULK1BRD4TP53BP1KITRIPK1 | |
| SCHEMBL18944113 | 0.86 | ULK1 (0.47) | ULK1BRD4TP53BP1KITRIPK1 | |
| SCHEMBL18932419 | 0.82 | PLK4 (0.52) | ULK1BRD4RIPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ULK1 495/4885BRD4 1388/4885FGFR3 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.